|
| Class |
Name |
Chemical name |
Risks |
| DEA Schedule III - |
Narcotic Compounded Medications |
Standard Prescriptions |
|
|
Tylenol#3 |
codeine, Tylenol |
A1, LT |
|
Empirin |
codeine, aspirin |
A1, GI |
|
Vicodin, Lorcet, Norco |
hydrocodone, Tylenol |
A1, LT |
|
Vicoprofen |
hydrocodone, ibuprofen |
A1, KT, GI |
|
Darvocet |
propoxyphene, Tylenol |
A1, LT |
|
Darvon |
propoxyphene, aspirin |
A1, GI |
| DEA Schedule II |
Narcotic Compounded Medications |
Triplicate or monitored prescription |
|
|
Percocet |
oxycodone, Tylenol |
A2, LT, WI |
|
Percodan |
oxycodone, aspirin |
A2, GI, WI |
| DEA Schedule II |
Narcotic Medications |
Triplicate or monitored prescription |
|
|
Dilaudid |
hydromorphone, tablet |
A3, MC, RD, WI |
|
Duragesic |
Fentanyl patch (q3 days) |
A3, MC, RD, WI |
|
Actiq |
Fentanyl oral swab - rapid action |
A3, MC, RD, WI |
|
Oxycontin |
oxycodone, slow release tablet (q12hr) |
A2, MC, RD, WI |
|
Oxy-IR |
oxycodone, fast release tablet |
A2, MC, RD, WI |
|
Demerol |
meperidine, injection or tablet |
A3, MC, RD, WI |
|
Kadian |
morphine, sustained release capsule (q12hr) |
A2, MC, RD, WI |
|
MS Contin |
morphine, slow release tablets (q12hr) |
A2, MC, RD, WI |
|
Avinza |
morphine, extended release capsule (q24hr) |
A2, MC, RD, WI |
|
|
|
All pain medications listed in the text and table of this site have side effects. In addition to those listed as special risks for each of these medications, there are serious but unusual side effects that occur rarely such as decreased production of blood cells by the body. All medications are risky for anyone who may be pregnant or who is breast feeding and require special attention before prescribing. With the exception of over-the-counter drugs, all of these medications should only be taken with a prescription for the patient and under the direction of a physician. Liver toxicity and kidney toxicity usually do not occur, but routine blood tests for signs of these problem are essential if they are taken on an ongoing basis. Narcotic drug dependency, addiction, and potiential for abuse are risks that can be controlled and monitored but are always a consideration when these medications are prescribed.
(A1) some addiction potential; (A2) significant addiction potential; (A3) high addiction potential (GI) gastric irritation; (KT) kidney toxicity; (LT) liver toxicity; (MC) mental clouding; (RD) respiratory depression; (WI) withdrawal risk. |
|
|